The PainSensor device is validated in more than 80 peer reviewed clinical studies showing that the indices increase during painful and nociceptive events. The index reacts within seconds and has low variation between individuals. It is based on skin sympathetic nerve activity with the nerve transmitter acetyl-choline acting on muscarinic receptors. The PainSensor index is therefore not influenced by temperature (22 °C – 42 °C), neuromuscular blockers (acting on nicotinic receptors), the hypotensive effect of alfa-2 agonists, epinephrines or beta-blockers as well as general hypoxia or changes in blood volume. In conscious patients in the peri-operative setting the index is not influenced by anxiety. The software includes indices for assessing awakening in uncounsious patients (too little anti-nociceptive drugs), withdrawal symptoms and the effect of regional nerve-block in the extremities within seconds. Med-Storm’s software can be installed on existing patient monitors (Philips and Masimo). Mindray and Draeger are in process. The PainSensor device is IP-protected, CE-certified and soon FDA approved. Read More.


• Obtained Eurostars grants, among the 10% best applications.
• “The best technology for clinical utility” promoted by the Society for Technology in Anesthesia, USA.
• Awards within Venture Cup, AstraZeneca’s pain research prize, “Reodor Felgen” Award No. 1 (Innovation Norway Entrepreneur prize)